Pharmacokinetics and tissue penetration of fluconazole in humans
- PMID: 2184510
- DOI: 10.1093/clinids/12.supplement_3.s318
Pharmacokinetics and tissue penetration of fluconazole in humans
Abstract
The pharmacokinetics and tissue/fluid penetration of fluconazole have been studied in more than 400 healthy individuals and various subsets of patients. The pharmacokinetics of fluconazole are similar following intravenous and oral dosing. Oral bioavailability is greater than 90%, and concentrations peak approximately 2 hours after dosing. The apparent volume of distribution is 0.7 L/kg, and plasma protein binding is low (12%). The drug is metabolically stable, with renal excretion accounting for approximately 80% of the elimination as unchanged drug. Repeated once-daily dosing results in an increase in plasma levels of approximately 2.5-fold, with steady state achieved by day 7. Plasma levels are dose-proportional, and the elimination rate remains constant across the dosage range and over time. The plasma half-life of fluconazole is approximately 30 hours. The pharmacokinetics are similar in healthy young adults and in the elderly, but dose modification is required in patients with renal impairment. Fluconazole diffuses readily into the cerebrospinal fluid, sputum, and saliva and is concentrated in the urine and skin.
Similar articles
-
Pharmacokinetics of fluconazole following intravenous and oral administration and body fluid concentrations of fluconazole following repeated oral dosing in horses.Am J Vet Res. 2001 Oct;62(10):1606-11. doi: 10.2460/ajvr.2001.62.1606. Am J Vet Res. 2001. PMID: 11592327
-
Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.Clin Pharmacokinet. 1997 Jul;33(1):52-77. doi: 10.2165/00003088-199733010-00005. Clin Pharmacokinet. 1997. PMID: 9250423
-
Pharmacokinetics of fluconazole in cats after intravenous and oral administration.Res Vet Sci. 1994 Nov;57(3):372-6. doi: 10.1016/0034-5288(94)90133-3. Res Vet Sci. 1994. PMID: 7871259 Clinical Trial.
-
Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility.Mycoses. 1997 Nov;40(7-8):259-65. doi: 10.1111/j.1439-0507.1997.tb00230.x. Mycoses. 1997. PMID: 9476508 Review.
-
The clinical pharmacology of fluconazole.Semin Oncol. 1990 Jun;17(3 Suppl 6):14-8. Semin Oncol. 1990. PMID: 2191442 Review.
Cited by
-
The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.Br J Clin Pharmacol. 2004 Jun;57(6):773-84. doi: 10.1111/j.1365-2125.2004.02073.x. Br J Clin Pharmacol. 2004. PMID: 15151523 Free PMC article. Clinical Trial.
-
Post-antifungal effect of the combination of anidulafungin with amphotericin B and fluconazole against fluconazole-susceptible and -resistant Candida albicans.Curr Med Mycol. 2022 Jun;8(2):8-15. doi: 10.18502/cmm.8.2.10327. Curr Med Mycol. 2022. PMID: 36654787 Free PMC article.
-
Effects of immunomodulatory and organism-associated molecules on the permeability of an in vitro blood-brain barrier model to amphotericin B and fluconazole.Antimicrob Agents Chemother. 2010 Mar;54(3):1305-10. doi: 10.1128/AAC.01263-09. Epub 2009 Dec 7. Antimicrob Agents Chemother. 2010. PMID: 19995929 Free PMC article.
-
Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Ex Vivo Model of Leishmania (Viannia) panamensis Infection.Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0142521. doi: 10.1128/AAC.01425-21. Epub 2021 Oct 25. Antimicrob Agents Chemother. 2022. PMID: 34694879 Free PMC article.
-
Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients.Eur J Clin Microbiol Infect Dis. 1996 Jun;15(6):446-52. doi: 10.1007/BF01691310. Eur J Clin Microbiol Infect Dis. 1996. PMID: 8839637
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical